VKORC1与CYP2C9基因多态性对新疆维吾尔族患者华法林日稳定剂量的影响(4)
[14] Gu Q,Kong Y,Schneede J,et al. VKORC1-1639G>A,CYP2C9,EPHX1691A>G genotype,body weight,and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China [J]. Eur J Clin Pharmacol,2010,66(12):1217-1227.
[15] Lee MT,Chen CH,Chou CH,et al. Genetic determinants of warfarin dosing in the Han-Chinese population [J]. Pharmacogenomics,2009,10(12):1905-1913.
[16] Cen HJ,Zeng WT,Leng XY,et al.CYP4F2 rs2108622:a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement [J]. Br J Clin Pharmacol,2010,70(2):234-240.
[17] 娄莹,华潞,韩璐璐,等.中国汉族人群华法林稳定剂量预测模型的建立与验证[J].中华心血管杂志,2014,42(5):384-388.
[18] 傅永平,张子彦.药理遗传学的方法指导心房颤动患者华法林使用剂量研究[J].中国现代医生,2014,52(32):151-154.
[19] 张浩,冯琳琳.基因指导的华法林用药研究[J].中国医药导报,2014,12(25):151-154,158.
[20] Gage BF,Eby C,Johnson JA,et al. Use of pharmacogenetics and clinical factors to predicte therapeutic dose of warfarin [J]. Clin Pharmacol Ther,2008,84(3):326-331.
(收稿日期:2016-02-28 本文编辑:苏 畅) (努尔子亚·曼那洪 帕提古丽·阿卜杜力 范芳芳 赵生)
[15] Lee MT,Chen CH,Chou CH,et al. Genetic determinants of warfarin dosing in the Han-Chinese population [J]. Pharmacogenomics,2009,10(12):1905-1913.
[16] Cen HJ,Zeng WT,Leng XY,et al.CYP4F2 rs2108622:a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement [J]. Br J Clin Pharmacol,2010,70(2):234-240.
[17] 娄莹,华潞,韩璐璐,等.中国汉族人群华法林稳定剂量预测模型的建立与验证[J].中华心血管杂志,2014,42(5):384-388.
[18] 傅永平,张子彦.药理遗传学的方法指导心房颤动患者华法林使用剂量研究[J].中国现代医生,2014,52(32):151-154.
[19] 张浩,冯琳琳.基因指导的华法林用药研究[J].中国医药导报,2014,12(25):151-154,158.
[20] Gage BF,Eby C,Johnson JA,et al. Use of pharmacogenetics and clinical factors to predicte therapeutic dose of warfarin [J]. Clin Pharmacol Ther,2008,84(3):326-331.
(收稿日期:2016-02-28 本文编辑:苏 畅) (努尔子亚·曼那洪 帕提古丽·阿卜杜力 范芳芳 赵生)